Schroder Ventures to fund only companies targeting middle class
By Venkatachari Jagannathan | 04 Sep 2000
"Our Indian focus is on companies whose products are directly used by the burgeoning middle class in India," declares Mr. Deepak Vaidya, country head, India, Schroder Capital Partners (Asia) Ltd. Industries that qualify under this classification are pharmaceutical, healthcare, retail and the like. "Segments like agriculture, steel, cement, infrastructure and even dot coms are out of our vision," he says.
According to him, Schroder Ventures has invested around $ 100 million in India out of its two Asia Pacific funds. He adds, "We haven’t concluded any major deals for our second fund, which has a corpus of $ 500 million."
Some of the Indian companies into which Schroder Ventures has put its money are Orchid Chemicals & Pharmaceuticals Ltd, Apollo Hospitals, Blue Dart. The Rs 175 crore investment in Orchid Chemicals is one of the biggest for the fund in the country. The investment has got the fund a berth in Orchid Chemicals'' board.
Though there is no lock-in period for its investment in Orchid Chemicals -- "We don’t accept any deals where there will be a lock-in period" -- Vaidya says that the fund sees Orchid Chemicals as a long term investment. It may be noted that Orchid Chemicals'' scrip, which went to dizzy heights to touch Rs 400-plus, came tumbling down after the union budget and after a not-so-inspiring performance last fiscal.
"Actually we are very much impressed with the Indian pharmaceutical industry as it has great potential for growth," says John Cheesmond, partner, Schroder Ventures Life Sciences Advisers (UK) Ltd, London, and a board member in Orchid Chemicals.
Interestingly, it seems Orchid Chemicals is charting its new growth plans upon the advice of Schroder Ventures. Says Mr Cheesmond, "The company has to consolidate its core activity in the bulk drug segment, get FDA approval for its plants to establish footprints in regulated markets and establish a formulation unit in India." And it is precisely this prescription that Orchid Chemicals is following.
Schroder Ventures, with its contacts in the pharmaceutical industry worldwide, is trying to locate a global partner for Orchid Chemicals in its endeavours, including doing contract research and global marketing of its products.
Latest articles
Featured articles
The decoupling paradox: Why Wall Street keeps funding AI despite $100 oil
By Axel Miller | 11 May 2026
AI infrastructure stocks continue rallying despite $100 oil as investors bet on productivity gains and semiconductor demand in 2026.
Hybrid bonding gains attention as AI chip packaging demand grows
By Cygnus | 23 Apr 2026
Hybrid bonding is driving AI chip packaging demand as backend technologies gain importance in the semiconductor supply chain.
The agentic transition: how enterprises are scaling AI from pilot to profit
By Cygnus | 22 Apr 2026
AI has entered its execution era. Discover how companies like Valeo and Microsoft are scaling agentic AI systems—from copilots to autonomous workflows driving real business impact.
Post-splashdown: What Artemis II taught us about the ‘deep space wall’
By Axel Miller | 15 Apr 2026
Artemis II splashdown marks a breakthrough in deep space exploration. Discover AVATAR radiation data, Orion’s distance record, and insights shaping NASA’s 2028 Moon mission.
Can aviation go green? The multi-billion dollar race for sustainable fuel
By Cygnus | 10 Apr 2026
Airlines are racing to adopt sustainable aviation fuel, but limited supply and high costs challenge the future of green aviation.
The battery race: who will control the future of electric vehicles?
By Axel Miller | 08 Apr 2026
The global battery race is reshaping the electric vehicle industry, with China, the US, and Europe competing for control over supply chains and technology.
AI vs governments: Who controls the future of intelligence?
By Cygnus | 07 Apr 2026
Governments and AI companies like OpenAI and Anthropic are shaping the future of intelligence amid rising policy conflicts and global competition.
Strait of Hormuz: how one chokepoint controls the global economy
By Axel Miller | 06 Apr 2026
The Strait of Hormuz is a critical global chokepoint. Learn how disruptions impact oil prices, shipping, and the global economy.
The $2 trillion AI infrastructure race: Who will control global compute?
By Cygnus | 06 Apr 2026
AI spending is set to exceed $2 trillion in 2026, driving a global race in data centers, chips, and energy infrastructure.


